Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06578247 · ClinicalTrials.gov registry record · Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
A Phase 3 study of Leukemia, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT06578247 is a Phase 3 study of Leukemia that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 700 participants, above the 484-participant average among 233 other Leukemia trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06578247, a Phase 3 study of Leukemia, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Chemotherapy
- DRUG Quizartinib
Study Locations (20)
California
- David Geffen School of Medicine - Los Angeles
- University of California Davis Health System - Sacramento
- Ucsf - School of Medicine - San Francisco
- Stanford University School of Medicine- Parent - Stanford
Florida
- Mayo Clinic Hospital - Jacksonville
- Florida Hospital Cancer Institute - Kissimmee - Kissimmee
- Tampa General Hospital - Tampa
- Moffitt Cancer Center - Tampa
Arizona
- City of Hope Phoenix - Goodyear
- Mayo Clinic - Phoenix - Phoenix
- University of Arizona Cancer Center - Tucson
Illinois
- Robert H Lurie Comprehensive Cancer Center Northwestern University - Chicago
- University of Illinois Hospital & Health Sciences System - Chicago
- The University of Chicago Medical Center - Chicago
Georgia
- Winship Cancer Institute of Emory University - Atlanta
- Augusta University - Augusta
Colorado
- Colorado Blood Cancer Institute - Denver
Connecticut
- Yale University - New Haven
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2030-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06578247
The ClinicalTrials.gov registry entry for NCT06578247 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 484-participant average among 233 other Leukemia trials with a reported enrollment target (45% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06578247 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06578247 about?
NCT06578247 is a clinical study titled "Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML". This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
What is the current status of trial NCT06578247?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2024-11-19. Estimated completion is 2030-06-26.
What conditions does trial NCT06578247 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT06578247?
The interventions under investigation include: Placebo (DRUG), Chemotherapy (DRUG), Quizartinib (DRUG).
Who is sponsoring clinical trial NCT06578247?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06578247 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
COMPLETED · Phase 3
-
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.